ALDERAAN BIOTECHNOLOGY

Modulating Immune
Cells to Treat Cancer

ALDERAAN BIOTECHNOLOGY

Mission

The mission of Alderaan Biotechnology is to develop novel therapies to treat cancer by targeting cells from the immune system.

Alderaan Biotechnology programs are related to the elimination of Regulatory T cells and to the hyper activation of Natural Killer cells in the tumor microenvironment.

ALDERAAN BIOTECHNOLOGY

Science

The company programs are based on the research of its two founding scientists on the use of monoclonal antibodies targeting immune cells to treat cancers. The objective of Alderaan Biotechnology is to develop new antibodies targeting NK cells through CD160-TM and Treg cells through CD25, with oncology as the sole indication focus.

CD25

Treg depletion using CD25-specific, IL2 and effector T-cell sparing antibodies

CD160TM

NK cell boost using CD160-TM specific monoclonal antibodies

ALDERAAN BIOTECHNOLOGY

Team

Meet our team of science, development and business professionals whose combined expertise helped create a unique company dedicated to cutting-edge drug discovery

ALDERAAN BIOTECHNOLOGY

News & Events

Alderaan Biotechnology raises € 18.5 million in the framework 706 424 fsena

Alderaan Biotechnology raises € 18.5 million in the framework

Alderaan Biotechnology, a preclinical stage company focused on monoclonal antibodies development for the treatment of…

read more

Find out all the news of
Alderaan Biotechnology